Haemonetics (HAE) Gets a Hold from Needham

Needham analyst Michael Matson maintained a Hold rating on Haemonetics (HAE – Research Report) today. The company’s shares opened today at $90.80.

Matson covers the Healthcare sector, focusing on stocks such as Paragon 28, Artivion, and Masimo. According to TipRanks, Matson has an average return of -6.3% and a 43.09% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Haemonetics with a $110.00 average price target.

Based on Haemonetics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $336.25 million and a net profit of $31.24 million. In comparison, last year the company earned a revenue of $305.3 million and had a net profit of $32.94 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Haemonetics (HAE) Company Description:

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.